GENEDX $WGS Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $123.1M (Est. $123M) 🟡; +5% YoY 🔹 Adj. EPS: $0.28 (Est. $0.07) 🟢 🔹 GAAP EPS: -$0.41 🔹 Exome & Genome Revenue: $110.4M; +12% YoY 🔹 Exome & Genome Volume: 32,134; +25% YoY 🔹 Non-GAAP Gross Margin: 72%; -200 bps YoY FY26 Guide: 🔹 Revenue: $475M-$490M (Est. $482M) 🟡 🔹 Exome & Genome Revenue Growth: At least 17% 🔹 Exome & Genome Volume Growth: At least 28% 🔹 Adjusted Gross Margin: ~71% 🔹 Adjusted Net Income: ~$12M Q4 Guide: 🔹 Revenue: $135M 🔹 Exome & Genome Revenue: $121M 🔹 Exome & Genome Volume: 34,500 tests 🔹 Adjusted Gross Margin: At least 71% 🔹 Adjusted Net Income: ~$12M Customers & Assets: 🔹 Accession Growth: +28% YoY Announcements: 🔹 GUARDIAN Study: 30,000 newborns enrolled; 72.3% parental participation 🔹 BRIDGES-NBS: Screen up to 30,000 newborns for 700+ conditions over two years Key Updates: 🔹 Adjusted Net Income: $8.6M 🔹 Medicaid Coverage: 25 state programs now cover whole genome sequencing 🔹 ASHG: 27 scientific abstracts presented Comments: 🔸 “Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth” 🔸 “Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale.”